1-(1H-benzo[d][1,2,3]triazol-1-yl)anthracene-9,10-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1-(1H-benzo[d][1,2,3]triazol-1-yl)anthracene-9,10-dione
• 英文别名: NSC80313；1-benzotriazol-1-yl-anthraquinone；1-Benzotriazol-1-yl-anthrachinon；1-(Benzotriazol-1-yl)anthracene-9,10-dione
• 化学式: C₂₀H₁₁N₃O₂
• 分子量: 325.326
• InChiKey: ZRQAKHIGSFKUOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(1H-benzo[d][1,2,3]triazol-1-yl)anthracene-9,10-dione 、 二苯胺 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Ullmann; Illgen, Chemische Berichte, 1914, vol. 47, p. 383

  摘要：

  DOI：
• 作为产物：
  描述：

  T406石油添加剂 、 1-氯蒽醌 在 potassium acetate 、 copper (I) acetate 、 硝基苯 作用下， 生成 1-(1H-benzo[d][1,2,3]triazol-1-yl)anthracene-9,10-dione
  参考文献：
  名称：

  Ullmann; Illgen, Chemische Berichte, 1914, vol. 47, p. 383

  摘要：

  DOI：

文献信息

• COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Universidad Andres Bello

  公开号：EP2897632A2

  公开（公告）日：2015-07-29
• COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION
  申请人：Augusta University Research Institute, Inc.

  公开号：EP3548022A1

  公开（公告）日：2019-10-09
• USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Universidad Andres Bello

  公开号：US20150337018A1

  公开（公告）日：2015-11-26

  The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, in the form of both non peptide compounds and peptides which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.
• [EN] USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] UTILISATION DE COMPOSÉS QUI MODULENT SÉLECTIVEMENT LA LIBÉRATION ASTROCYTAIRE DE SUBSTANCES PAR LES HÉMICANAUX DE CONNEXINE ET DE PANNEXINE, SANS INFLUENCER LES JONCTIONS COMMUNICANTES, POUR LE TRAITEMENT DES TROUBLES PSYCHIATRIQUES
  申请人：UNIV ANDRES BELLO

  公开号：WO2013179264A2

  公开（公告）日：2013-12-05

  The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, in the form of both non peptide compounds and peptides which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.
• [EN] COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION<br/>[FR] COMPOSITIONS POUR MODULER LA TRANSDUCTION DU SIGNAL PD-1
  申请人：UNIV RES INST INC AUGUSTA

  公开号：WO2018100556A1

  公开（公告）日：2018-06-07

  Several compounds have been discovered that modulate signal transduction through the PD-1 receptor. In certain embodiments, the compounds promote or induce an activating signal through the PD-1 receptor that activates a T cell. The compounds can bind to PD-1 and inhibit or prevent ligands from binding to PD-1 and thereby suppress inhibitory signal transduction through the PD-1 receptor.